CRH Medical (CRHM) Cut to Hold at Zacks Investment Research

CRH Medical (NYSEAMERICAN:CRHM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Thursday.

According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “

How to Become a New Pot Stock Millionaire

CRHM opened at $2.75 on Thursday. CRH Medical has a 1-year low of $1.46 and a 1-year high of $9.25.

CRH Medical (NYSEAMERICAN:CRHM) last posted its quarterly earnings results on Monday, March 5th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $32.30 million during the quarter, compared to the consensus estimate of $27.35 million.

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. bought a new position in CRH Medical during the 2nd quarter worth $150,000. Ramsey Quantitative Systems acquired a new stake in shares of CRH Medical during the 4th quarter worth $128,000. TD Asset Management Inc. grew its holdings in shares of CRH Medical by 65.3% during the 3rd quarter. TD Asset Management Inc. now owns 111,054 shares of the company’s stock worth $289,000 after purchasing an additional 43,851 shares in the last quarter. Baird Financial Group Inc. acquired a new stake in shares of CRH Medical during the 4th quarter worth $301,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of CRH Medical by 69.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 410,100 shares of the company’s stock worth $964,000 after purchasing an additional 167,600 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “CRH Medical (CRHM) Cut to Hold at Zacks Investment Research” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3336675/crh-medical-crhm-cut-to-hold-at-zacks-investment-research.html.

CRH Medical Company Profile

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

Get a free copy of the Zacks research report on CRH Medical (CRHM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Proteostasis Therapeutics Stock Price
FTD Companies  Getting Somewhat Positive Press Coverage, Report Shows
FTD Companies Getting Somewhat Positive Press Coverage, Report Shows
Koovs  Stock Price Up 28.2%
Koovs Stock Price Up 28.2%
Rigel Pharmaceuticals   Shares Down 6.5%
Rigel Pharmaceuticals Shares Down 6.5%
Dicerna Pharmaceuticals  Shares Up -6.6%
Dicerna Pharmaceuticals Shares Up -6.6%
Barnes & Noble  & Big 5 Sporting Goods  Head to Head Review
Barnes & Noble & Big 5 Sporting Goods Head to Head Review


© 2006-2018 Ticker Report. Google+.